Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.
Latest from Jung Won Shin
Plus deals involving Nippon Shinyaku/Atsena, Daiichi Sankyo/Alteogen, Santen/Arctic Vision, Henlius/SVAX, Nxera/Antiverse, Y-mAbs/Nobelpharma, Formosa/DAVI, Mochida/United Therapeutics, GSK/Chimagen and GC/Novelty Nobility.
Yuhan eyes successors to lazertinib after US approval, leadership dispute at Hanmi drags on and SK Bioscience completes CDMO acquisition.
A session at the recent KoNECT conference in Seoul looked at Korea’s strengths in clinical trials but also at what's needed to further improve its global competitiveness as a location for studies.
Oscotec co-CEO Taeyoung Yoon highlights anti-resistance and anti-tau therapies as the Korean bioventure’s next possible blockbuster candidates after the landmark US approval of lazertinib for lung cancer.
The five-year roadmap aims to expand support for AI research and development in essential health care and new drug development, as well as advance medical data usage systems and enable its safe use.
Following strong demand for offerings by D&D Pharmatech and ENCell, sentiment around biopharma IPOs in Korea appears to be improving, with several other ventures planning to float.